Antibodies, Bispecific

"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.

Descriptor ID	D018033
MeSH Number(s)	D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
Concept/Terms	Antibodies, Bispecific Antibodies, Bispecific Bispecific Antibodies Bifunctional Antibodies Antibodies, Bifunctional Bispecific Monoclonal Antibodies Bispecific Monoclonal Antibodies Antibodies, Bispecific Monoclonal Monoclonal Antibodies, Bispecific

Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Bispecific [D12.776.124.486.485.114.125]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Bispecific [D12.776.124.790.651.114.134]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Bispecific [D12.776.377.715.548.114.134]

Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.

Bar chart showing 32 publications over 15 distinct years, with a maximum of 4 publications in 2020 and 2021 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	1	0	1
2001	1	0	1
2008	0	2	2
2012	0	1	1
2015	0	1	1
2016	1	1	2
2017	0	2	2
2018	2	0	2
2019	1	0	1
2020	4	0	4
2021	4	0	4
2022	2	0	2
2023	4	0	4
2024	1	2	3
2025	0	2	2

Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.

Kalavar M, Sridhar J. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol. 2025 May 01; 36(3):189-198.

View in: PubMed
Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025 04; 56(4):206-211.

View in: PubMed
Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024 Jun 06; 12(6).

View in: PubMed
Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024; 20(30):2241-2248.

View in: PubMed
Palecki J, Bhasin A, Bernstein A, Mille PJ, Tester WJ, Kelly WK, Zarrabi KK. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. Cancer Biol Ther. 2024 12 31; 25(1):2356820.

View in: PubMed
Momenaei B, Wang K, Kazan AS, Oh GJ, Ni RL, Wakabayashi T, Durrani AF, Kuriyan AE, Klufas MA, Garg SJ, Yonekawa Y, Hsu J. Rates of Ocular Adverse Events after Intravitreal Faricimab Injections. Ophthalmol Retina. 2024 03; 8(3):311-313.

View in: PubMed
Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, Pashaee B, Kazan AS, Ho AC, Klufas M, Regillo C, Yonekawa Y, Hsu J, Kuriyan A, Chiang A. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2024 04; 8(4):360-366.

View in: PubMed
Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, Zhang T, Mei Q, Chu Q, Wu K. Synergistic efficacy of simultaneous anti-TGF-?/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023 08 12; 16(1):94.

View in: PubMed
Curtis R, Roberts JC, Crook N, Decker-Palmer M, Khainar R, Baker JR, Ullman M, Koerper MA, Wu J, Nichol MB. Trends in prescribing practices for management of haemophilia: 1999-2021. Haemophilia. 2023 May; 29(3):761-769.

View in: PubMed
Yi M, Niu M, Wu Y, Ge H, Jiao D, Zhu S, Zhang J, Yan Y, Zhou P, Chu Q, Wu K. Combination of oral STING agonist MSA-2 and anti-TGF-?/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol. 2022 10 08; 15(1):142.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement